Kinetic Concepts' 28-year overnight success story rests on an opportunistic acquisition designed to complement its core business in specialty beds designed to prevent or relieve wounds caused by patient immobility. In 1994, KCI acquired rights to the VAC (Vacuum Assisted Closure) Therapy System, a non-invasive wound closure device that uses controlled, localized negative pressure to help promote healing in chronic and acute wounds. VAC is now the company's principal growth driver, accounting for 71% of the company's revenues, and a growth rate of 28%. VAC has been everything that KCI hoped--and much more. But now, in order to penetrate the $3.3 billion markets that it is targeting, the company will have to move beyond the core hospital markets where it's been successful, to the more challenging extended care and home health care markets.
By Mary Stuart
Kinetic Concepts Inc. (KCI) headed the list of best-performing IPOs in 2004 by finishing the year with an almost 150% gain. Having started trading at a price of $30...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
